) are detected in about 50% of lesions from patients with metastatic melanoma. In the last few years, clinical treatment of melanoma has benefited from the approval of personalised therapies targeting BRAFV600. These innovative therapies still require molecular biomarkers predicting response duration. Circulating tumour DNA (ctDNA) appears to be a promising tool thanks to its ability to capture tumour heterogeneity. Detection of BRAF V600mut in ctDNA (ctBRAF
V600mut
) could be a hopeful tool to monitor and predict clinical response in melanoma treated with BRAF/MEK inhibitors.
Low baseline levels (pretreatment initiation) of ctBRAF V600mut have been found to be significantly associated with longer progression-free survival (PFS) and variation in ctBRAF V600mut levels during treatment was associated with the clinical course. 1 2 Similarly, overall survival (OS) was significantly associated with BRAF V600mut status in ctDNA prior to any targeted therapy. 3 Furthermore, a significantly higher PFS was found for patients in whom ctBRAF
V600mut became undetectable at some time point after initiation of targeted therapy. 4 From 2012 to 2014, 85 patients from the onco-dermatology department of the SaintLouis Hospital (Paris, France) presenting unresectable stage III (n=12) or stage IV (n=73) melanoma with BRAF V600E mutated lesions at targeted therapy initiation (BRAF inhibitors, vemurafenib or dabrafenib) were included in this retrospective study after signed informed consent. The cohort included 52 (62%) patients presenting a stage IV m1c melanoma, and 23 (27%) had brain metastasis. Clinical response was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) V.1.1 criteria.
Detection of ctBRAF
V600mut was monitored at baseline and during therapy using the highly sensitive E-ice-COLD-PCR method (0.1% sensitivity threshold). 5 The aim was to study the potential of BRAF V600mut detection in ctDNA as a predictor of tumour escape at baseline and at early intervals after therapy initiation.
Consistent with previous studies, 1 Figure 1 Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (<3 months) after targeted therapy initiation (n=30) compared with patients without BRAFV600-mutated ctDNA at the first visit (<3 months) after targeted therapy initiation (n=23). ctDNA, circulating tumour DNA; PFS, progression-free survival.
clinical practice. As the pretreatment ctBRAF V600mut status and the longitudinal monitoring are rarely performed in daily clinical practice, our results show the clinical value of BRAF V600mut detection in ctDNA early after initiation of targeted therapy (<3 months). Such tool may allow the anticipation of clinical response and assessment of secondary resistance, hence facilitating earlier management of melanoma patients treated with targeted therapies.
Contributors BL analysed and interpreted the data and drafted the manuscript. JT performed the molecular analyses and contributed to data collection, study design and writing of the manuscript. FM and AH-K performed the molecular analyses and contributed to data collection and assembly. AS and M-PP provided a technical support. CP and JR provided clinical data. LDM performed clinical data management. CL provided her expertise in the melanoma field, designed the study and wrote the manuscript. SM designed the study, interpreted the data and wrote the manuscript.
